Information Provided By: 
Fly News Breaks for August 3, 2015
TRIB
Aug 3, 2015 | 09:14 EDT
Stephens named Trinity Biotech as its "Best Idea" for the second half of the year as the firm sees the company's FDA submission for its Meritas troponin product, which is expected in late August or early September, as the best catalyst in its coverage space. The firm, which also noted it is comfortable with estimates for the remainder of the year after Q2, has a $22 price target and Overweight rating on Trinity shares.
News For TRIB From the Last 2 Days
There are no results for your query TRIB
